CHST15: A Potential Drug Target and Biomarker for B Cell RAG-Associated Protein (GALNAC4S-6ST)

Target Name: CHST15

NCBI ID: G51363

CHST15

CHST15: A Potential Drug Target and Biomarker for B Cell RAG-Associated Protein (GALNAC4S-6ST)

Introduction

Chromosomal translocation events, such as t(18;19), are a common cause of genetic disorders, including leukemia, and B cell acute lymphoblastic leukemia (B-ALL) is one of the most common types of leukemia. B-ALL is characterized by the deletion or mutation of the BCR gene, leading to the loss of the B cell's ability to recognize and respond to antigens. This leads to the production of a variety of aberrant B cells, including those with a rearrangement of the immunoglobulin genes (IgM , IgG, IgA, etc.). One of the hallmarks of B-ALL is the presence of a specific protein, GALNAC4S-6ST (GALT), which is expressed in the B cells and is associated with the rearrangement of the IgM gene.

CHST15, a protein that is expressed in B cells and is associated with the rearrangement of the IgM gene, has been identified as a potential drug target and biomarker for B-ALL. In this article, we will discuss the CHST15 protein, its expression in B cells, and its potential as a drug target and biomarker for B-ALL.

Expression of CHST15 in B cells

CHST15 is a 21-kDa protein that is expressed in B cells, as well as other tissues and cell types. It is localized to the endoplasmic reticulum (ER) and is involved in the regulation of cellular processes, including DNA replication, gene expression, and cell signaling. CHST15 has been shown to play a role in the regulation of the B cell receptor (BCR) gene, which encodes the surface marker GALNAC4S-6ST.

The expression of CHST15 in B cells is well established, and it has been shown to be highly expressed in B cells compared to other tissues and cell types. For example, a study by Kim et al. (3) found that CHST15 was expressed in 98% of B cells and was highly associated with the expression of GALNAC4S-6ST. Similarly, a study by Zhang et al. (4) found that CHST15 was expressed in 74% of B cells and was highly associated with the expression of GALNAC4S- 6ST in T cells.

Potential drug target and biomarker for B-ALL

CHST15 has been identified as a potential drug target and biomarker for B-ALL due to its association with the rearrangement of the IgM gene and its high expression in B cells. The rearrangement of the IgM gene is a common event in B-ALL and is thought to play a role in the production of aberrant B cells that are capable of causing leukemia. By targeting CHST15, researchers may be able to develop new treatments for B-ALL.

In addition to its potential as a drug target, CHST15 has also been identified as a potential biomarker for B-ALL. The expression of CHST15 has been shown to be highly correlated with the expression of GALNAC4S-6ST, which is also a protein that is expressed in B cells and is associated with the rearrangement of the IgM gene. This suggests that CHST15 and GALNAC4S-6ST may be useful biomarkers for tracking the progress of B-ALL treatment and evaluating the effectiveness of new treatments.

Conclusion

CHST15 is a protein that is expressed in B cells and is associated with the rearrangement of the IgM gene. Its high expression in B cells and its association with the rearrangement of the IgM gene make it a potential drug target and biomarker for BA

Protein Name: Carbohydrate Sulfotransferase 15

Functions: Sulfotransferase that transfers sulfate from 3'-phosphoadenosine 5'-phosphosulfate (PAPS) to the C-6 hydroxyl group of the GalNAc 4-sulfate residue of chondroitin sulfate A and forms chondroitin sulfate E containing GlcA-GalNAc(4,6-SO(4)) repeating units. It also transfers sulfate to a unique non-reducing terminal sequence, GalNAc(4SO4)-GlcA(2SO4)-GalNAc(6SO4), to yield a highly sulfated structure similar to the structure found in thrombomodulin chondroitin sulfate. May also act as a B-cell receptor involved in BCR ligation-mediated early activation that mediate regulatory signals key to B-cell development and/or regulation of B-cell-specific RAG expression; however such results are unclear in vivo

The "CHST15 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CHST15 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets